The pipeline is "deep", thin and weak. They will burn their money trying to bring a drug to market. Amgen used JNJ to get their EPO drug to market, and you can read all about their kickback scheme and intentional overfilling of their own Aracept while shorting Procrit volumes for JNJ. If ARRY had anything UNIQUE and of real value, they'd get bought out, or get an offer like Amgen got way back when. Heck, they're pretty cheap as a buyout now. Maybe Warren Buffet can buy ARRY for Berkshire, rather than that coal-shipping train company? There's a vote for our future - shipping coal, and expecting a government too broke to repair our highways for truckers, with gas prices skyrocketing due to inflation and a worthless dollar.

If ARRY had a few FOCUSED hits moving down their pipeline, rather than diluting it with so many money burning "hits", investors might give them their money. Until they make some intelligent choices and pull some lures out of the water, money will sit on the sidelines.